Hailir Pharmaceutical Group 2021 Semi-annual Report

     On August 28, the company released the 2021 semi-annual report. In the first half of 2021, the company realized operating income of 1.959 billion yuan; realized net profit attributable to shareholders of listed companies of 228 million yuan; weighted average return on equity 8.38%; the company’s basic per share The income is 0.68 yuan.

     The business performance in the first half of 2021 was mainly due to: during the period of upward fluctuations in the prices of some of the pesticides and raw materials, the production and supply were stabilized, the gross profit was reduced, and the revenue still achieved a certain increase; The improvement of environmental protection maintenance and technical reform has affected the operating rate to a certain extent. The prices of some major products are currently trending better compared with the same period last year. It is expected that there will be a certain positive impact on the performance of the second half of the year. At the same time, it is affected by exchange losses and equity incentive payment fees. Short-term performance is subject to certain fluctuations. On the whole, the company achieved overall revenue growth in the first half of 2021, stable operating net cash flow, strong comprehensive profitability, and good operating conditions.

     In the future, Hailir will focus on seven core sub-strategies, including human development strategy, technology leadership and continuous innovation strategy, efficient operation strategy, international market development strategy, sustainable development strategy of technical materials, crop technology service strategy, and industrial chain layout strategy. Support and achieve the strategic goal of building a professional service platform for the entire agricultural industry chain.